ST天圣(002872) - 2022 Q2 - 季度财报

Financial Performance - The company's operating revenue for the first half of 2022 was ¥270,348,302.21, a decrease of 45.38% compared to ¥495,001,560.78 in the same period last year[24]. - The net loss attributable to shareholders was ¥46,492,423.29, representing a 14.85% increase in loss from ¥40,479,749.05 in the previous year[24]. - The basic and diluted earnings per share were both -¥0.1462, a decline of 14.85% from -¥0.1273 in the previous year[24]. - The total revenue for the first half of 2022 was 107,879 million, a decrease from 79,869 million in the previous period[77]. - The net profit for the first half of 2022 was a loss of CNY 47,031,793.65, compared to a loss of CNY 40,959,839.83 in the first half of 2021, indicating a deterioration of approximately 14.5%[188]. - The total comprehensive income for the first half of 2022 was CNY -47,031,793.65, compared to CNY -40,959,839.83 in the first half of 2021, reflecting a decline of approximately 14.5%[188]. Cash Flow and Investments - The net cash flow from operating activities improved by 20.80%, amounting to -¥53,554,623.52 compared to -¥67,621,441.88 in the previous year[24]. - The company reported a net cash flow from operating activities of -¥53,554,623.52, an improvement of 20.82% compared to -¥67,621,441.88 in the previous year[56]. - The net cash flow from investment activities was -94,598,710.31 CNY for the first half of 2022, worsening from -30,213,541.00 CNY in the same period of 2021[194]. - The net cash flow from financing activities was 45,882,460.45 CNY in the first half of 2022, a turnaround from -30,907,321.76 CNY in the first half of 2021[194]. - The company reported a significant increase in cash inflow from the recovery of investments, reaching 522,683,019.82 CNY in the first half of 2022, compared to 94,758,332.37 CNY in the same period of 2021[195]. Assets and Liabilities - Total assets decreased by 5.88% to ¥2,936,651,899.84 from ¥3,120,025,480.00 at the end of the previous year[24]. - The company's total assets decreased from ¥338,675,754 to ¥196,832,810, with a notable reduction in cash and cash equivalents from 10.85% to 6.70% of total assets[62]. - The company's long-term borrowings decreased from ¥155,373,643 to ¥109,504,282, reflecting a 1.25% reduction in the proportion of total liabilities[62]. - The total liabilities decreased to ¥1,200,000,000.00, reflecting a reduction in financial obligations[178]. - The company's non-current liabilities due within one year increased from ¥53,626,474.2 to ¥113,329,162.0, reflecting a rise of 2.14%[63]. Research and Development - Research and development expenses increased by 9.15% to ¥14,050,556.75 from ¥12,872,350.45, indicating a continued focus on innovation[56]. - The company has established a research institute focusing on innovative drugs, improved new drugs, and deep development of traditional Chinese medicine, attracting top research talent[40]. - The company aims to increase its R&D investment by 10% in the upcoming fiscal year to support innovation[199]. Market and Industry Outlook - The pharmaceutical industry is expected to grow due to increasing chronic disease prevalence and supportive government policies[33]. - The company is engaged in drug research, production, and sales, with a focus on modernizing traditional Chinese medicine[34]. - The company has seen a rise in market demand for traditional Chinese medicine, driven by recent policy support and integration with Western medicine[34]. - The company is facing risks related to industry policies, including stricter regulations and price controls, which could impact future growth[86]. Corporate Governance and Compliance - The company emphasizes strict compliance with laws and regulations to protect the rights of shareholders and creditors, enhancing corporate governance and internal control systems[113]. - The company has implemented a system for managing insider information to ensure fair and transparent information disclosure practices[113]. - The company is currently involved in a significant legal case regarding bribery allegations, which may affect its operations and financial standing[90]. Environmental Responsibility - The company is classified as a key pollutant discharge unit by environmental protection authorities[102]. - The company reported that all monitored pollutants were within the permitted discharge limits, with no exceedances noted[102]. - The company has established a comprehensive emergency response plan for environmental incidents, which has been reviewed and filed by experts[108]. Shareholder Information - The company raised a total of RMB 1,185.61 million through the issuance of 53 million shares at a price of RMB 22.37 per share, with a net amount of RMB 1,078.79 million after expenses[74]. - The total number of shares is 318,000,000, with 100% ownership by the shareholders[161]. - Liu Qun holds 32.89% of the total shares, amounting to 104,590,532 shares, with 1,628,800 shares pledged[164]. Related Party Transactions - The total amount of related party transactions in the first half of 2022 was approximately 131.7 million yuan, accounting for 1.40% of similar transactions[135]. - The company reported a receivable from related parties of 162.81 million yuan, with a year-end balance of 147.47 million yuan[140]. - The company did not experience significant differences between transaction prices and market reference prices in related party transactions[137].